Charles Stanley issued a “buy” note on the recruitment giant following signs that having been one of the first sectors to enter the recession, it may be the first to exit. The broker said concerns that the group’s exposure to the finance, accounting and banking sectors have somewhat dissipated ahead of preliminary results this Thursday.

Evolution Securities said the commercial property group’s results had been as expected although it had been a turbulent year. Letting progress in the fourth quarter was palpably better than in the preceeding nine months and progress on letting will enhance asset values as near term voids are transformed into cash, it added.

Execution Noble reiterated its “Buy” stance following Ark and Oxford Biomedica’s trial failures, Antisoma is now firmly established as the UK cancer pure play. With two cancer drugs reporting Phase III data over the next 18 months, the company is moving to the late-stage. The broker said the risk/reward is attractive at these levels.

To appear in Best of the Brokers email your research to